{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NASDAQ/INMB",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Inmune Bio, Inc. (NASDAQ: INMB) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Inmune Bio, Inc., listed on NASDAQ under ticker INMB, with ISIN US45782T1051. The LEI is not on the record, as no GLEIF record carries the exact legal name in jurisdiction US-NV. The security type is Corporate, the sector is 2836 Biological Products, (No Diagnostic Substances), and the jurisdiction is United States, Nevada. The segment is not on the record. The issuer is listed and not halted.\n\n## The disclosure read\n\nThe record holds 53 filings in the twelve months to 2026-11-08, across 34 filing days. The median gap between filing days is 7 days. The latest filing is dated 2026-11-05, is of type results, and falls 3 days before the record date. The NASDAQ median cadence gap is 6.0 days across 4359 issuers, and the NASDAQ median latency is 5.0 days. The sector median cadence gap is 5.5 days across 176 issuers, and the sector median latency is 4.0 days. The NASDAQ median filings count is 52, and the sector median filings count is 65.5. The filings by type are: corporate_news 18, directors_dealings 21, director_change 5, results 4, prospectus 2, ad_hoc 1, agm_egm 1, and regulatory_filing 1.\n\n## Auditor\n\nThe auditor of record is CBIZ CPAs P.C., located in Houston, Texas. The record holds no auditor changes.\n\n## Events and halts\n\nThe record carries one listing line, dated 2025-12-08. It carries no delisting, no name change, and no domicile change, and the domicile change is not on the record. The segment move is not on the record. The halt flag is listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nNone found. The issuer's investor-relations page names no research houses.\n\n## Open research\n\nNone found. The record holds no openly published research notes.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe issuer is sealed for the years 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.\n\n## Sources\n\n8 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)\n- https://data.sec.gov/submissions/CIK0001711754.json (identity.jurisdiction)\n- https://mcp.us-cm-kg.ai/events/NASDAQ/INMB (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://www.sec.gov/Archives/edgar/data/1711754/000121390026036370/ea0279078-10k_inmune.htm (the auditor)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://mcp.us-cm-kg.ai/record/NASDAQ/INMB (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1711754/000121390026036370/ea0279078-10k_inmune.htm",
    "state": "sourced",
    "value": "CBIZ CPAs P.C."
   },
   "auditor_firm_id": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1711754/000121390026036370/ea0279078-10k_inmune.htm",
    "state": "sourced",
    "value": "199"
   },
   "auditor_location": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1711754/000121390026036370/ea0279078-10k_inmune.htm",
    "state": "sourced",
    "value": "Houston, Texas"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NASDAQ/INMB",
  "coverage": {
   "count": 0,
   "houses": [],
   "pages_checked": [],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": null,
   "state": "none_found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 4359,
     "median_cadence_gap_days": 6,
     "median_filings": 52,
     "median_latency_days": 5,
     "name": "NASDAQ"
    },
    "sector": {
     "issuers": 176,
     "median_cadence_gap_days": 5.5,
     "median_filings": 65.5,
     "median_latency_days": 4,
     "name": "2836 Biological Products, (No Diagnostic Substances)"
    }
   },
   "by_type": {
    "ad_hoc": 1,
    "agm_egm": 1,
    "corporate_news": 18,
    "director_change": 5,
    "directors_dealings": 21,
    "prospectus": 2,
    "regulatory_filing": 1,
    "results": 4
   },
   "cadence_median_gap_days": 7,
   "filing_days": 34,
   "filings": 53,
   "latency_days": 3,
   "latest": [
    {
     "category": "10-Q",
     "date": "2026-11-05",
     "source": "https://www.sec.gov/Archives/edgar/data/1711754/000121390026116359/ea0309228-10q_inmune.htm",
     "title": "10-Q — QUARTERLY REPORT",
     "type": "results"
    },
    {
     "category": "8-K",
     "date": "2026-10-29",
     "source": "https://www.sec.gov/Archives/edgar/data/1711754/000121390026113535/ea0309967-8k_inmune.htm",
     "title": "8-K — CURRENT REPORT (items 1.01,3.02,7.01,9.01)",
     "type": "corporate_news"
    },
    {
     "category": "424B5",
     "date": "2026-10-29",
     "source": "https://www.sec.gov/Archives/edgar/data/1711754/000121390026113531/ea0308597-424b5_inmune.htm",
     "title": "424B5 — PROSPECTUS SUPPLEMENT",
     "type": "prospectus"
    },
    {
     "category": "8-K",
     "date": "2026-10-21",
     "source": "https://www.sec.gov/Archives/edgar/data/1711754/000121390026111207/ea0309223-8k_inmune.htm",
     "title": "8-K — CURRENT REPORT (items 7.01,8.01,9.01)",
     "type": "corporate_news"
    },
    {
     "category": "4",
     "date": "2026-09-23",
     "source": "https://www.sec.gov/Archives/edgar/data/1711754/000121390026102342/xslF345X06/ownership.xml",
     "title": "4",
     "type": "directors_dealings"
    }
   ],
   "latest_filing_date": "2026-11-05",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/INMB",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NASDAQ"
   },
   "isin": {
    "read_by": "SEC Fails-to-Deliver data (CUSIP for the symbol) · ISIN = US + CUSIP + ISO 6166 check digit",
    "read_date": "2026-10-05",
    "read_date_basis": "last_seen",
    "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data",
    "state": "sourced",
    "value": "US45782T1051"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001711754.json",
    "state": "sourced",
    "value": "United States — Nevada"
   },
   "lei": {
    "market": "US",
    "reason": "no GLEIF record with the exact legal name in jurisdiction US-NV",
    "state": "not_on_record"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001711754.json",
    "state": "sourced",
    "value": "Inmune Bio, Inc."
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001711754.json",
    "state": "sourced",
    "value": "2836 Biological Products, (No Diagnostic Substances)"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001711754.json",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "INMB"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [
    {
     "date": "2025-12-08",
     "source": "https://www.sec.gov/Archives/edgar/data/1711754/000121390025119251/ea0268668-8a12ba5_inmune.htm",
     "title": "8-A12B/A — AMENDMENT NO. 5 TO FORM 8-A12B"
    }
   ],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:a4d64680913808b9fcf1cd3161f1875f7a300761fbb322ffb6636425c5ead633",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NASDAQ/INMB",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:a4d64680913808b9fcf1cd3161f1875f7a300761fbb322ffb6636425c5ead633",
 "path": "/us/NASDAQ/INMB",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is Inmune Bio, Inc., listed on NASDAQ under ticker INMB, with ISIN US45782T1051. The LEI is not on the record, as no GLEIF record carries the exact legal name in jurisdiction US-NV. The security type is Corporate, the sector is 2836 Biological Products, (No Diagnostic Substances), and the jurisdiction is United States, Nevada. The segment is not on the record. The issuer is listed and not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 53 filings in the twelve months to 2026-11-08, across 34 filing days. The median gap between filing days is 7 days. The latest filing is dated 2026-11-05, is of type results, and falls 3 days before the record date. The NASDAQ median cadence gap is 6.0 days across 4359 issuers, and the NASDAQ median latency is 5.0 days. The sector median cadence gap is 5.5 days across 176 issuers, and the sector median latency is 4.0 days. The NASDAQ median filings count is 52, and the sector median filings count is 65.5. The filings by type are: corporate_news 18, directors_dealings 21, director_change 5, results 4, prospectus 2, ad_hoc 1, agm_egm 1, and regulatory_filing 1.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is CBIZ CPAs P.C., located in Houston, Texas. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record carries one listing line, dated 2025-12-08. It carries no delisting, no name change, and no domicile change, and the domicile change is not on the record. The segment move is not on the record. The halt flag is listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "None found. The issuer's investor-relations page names no research houses.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "None found. The record holds no openly published research notes.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The issuer is sealed for the years 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "8 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.isin",
   "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0001711754.json"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/INMB"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the auditor",
   "source": "https://www.sec.gov/Archives/edgar/data/1711754/000121390026036370/ea0279078-10k_inmune.htm"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NASDAQ/INMB"
  }
 ],
 "title": "Inmune Bio, Inc. (INMB) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}